Ability Pharma (private company)

AbilityPharma is a clinical-stage biopharmaceutical company focused on developing first-in-class causing autophagy molecules through binding to the nuclear receptors PPARα and PPARγ and inducing Reticular Stress (ER-Stress).  It represents a novel approach, offering an opportunity to create important new therapeutic options for cancer patients.